SAN ANTONIO--New research suggests that abnormalities in the BRCA1 gene may be involved in the pathogenesis of sporadic breast cancers as well as familial breast and ovarian cancers.
SAN ANTONIO--New research suggests that abnormalities in the BRCA1gene may be involved in the pathogenesis of sporadic breast cancersas well as familial breast and ovarian cancers.
The investigators, from the University of Texas Health ScienceCenter at San Antonio, found that in normal breast epithelialcells and in cells from other types of cancer, the BRCA1 proteinis contained in the cell nucleus.
In contrast, BRCA1 was found in the cell cytoplasm in almost allbreast cancer cell lines tested (all derived from advanced, metastaticcancers), as well as in all 17 samples of malignant pleural effusionsfrom breast cancer patients (Science 270:789-791, 1995).
In primary breast tumors, the BRCA1 protein was less likely tobe mislocated: It was found in the nucleus in eight cases, inthe cytoplasm in six, absent in two, and in both cell locationsin 34 samples studied.
"The subcellular mislocation of the BRCA1 protein suggeststhat abnormalities in BRCA1 are fundamental to the genesis orprogression of most breast cancers," said Dr. Wen-Hwa Lee,lead investigator. In sporadic cases, he said, BRCA1 may be inactivatedindirectly by the mislocation of the protein in the cytoplasm,whereas in hereditary breast cancers, the inactivation stems directlyfrom intragenic mutations.
Because the aberration was more likely to be found in metastaticthan in primary breast cancers, the mislocation of the proteincould indicate more aggressive disease. The researchers plan totest this hypothesis by determining the protein location in upto 1,000 tumor cells stored at the university and correlatingthe results with disease outcome.
Experts Discuss Differences in Radiotherapy Outcomes in BRCA+ Breast Cancer
October 30th 2023Rebecca M. Shulman, MD, and Zachary Kiss, DO, discuss findings from a study evaluating differences in outcomes with radiotherapy and disease characteristics of patients with breast cancer harboring BRCA mutations compared with those without mutated disease.
FDA Approves Capivasertib Plus Fulvestrant in Advanced HR+, HER2– Breast Cancer
November 16th 2023Patients with locally advanced or metastatic breast cancer that is hormone receptor–positive, HER2-negative breast cancer with 1 or more PIK3CA, AKT1, or PTEN alterations may now receive capivasertib plus fulvestrant.
Oncology On-The-Go Podcast: De-escalating Breast Cancer Treatment
May 8th 2023Rakhshanda Rahman, MD, FRCS, FACS, emphasizes the importance of educating patients and physicians on the potential risks and benefits of new approaches and technologies involved in the de-escalation of breast cancer treatment.